SHANGHAI, China – January 2, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, ‘Everest’, or the ‘Company’), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List (“NRDL”) on January 1…
Read More
